You are here: Industry Insights > schizophrenia

News List

Burden of Rare Genetic Variants Higher in Severe Schizophrenia Drugs
December 14, 2021
Individuals with severe, extremely treatment-resistant schizophrenia have an increased burden of high-impact rare genetic variants, according to a study published in the Dec. 21 issue...
Could Heavy Marijuana Use Be Driving Rise in Schizophrenia Cases? drugs
July 28, 2021
There's been a sharp rise in schizophrenia cases linked with marijuana use since the mid-1990s, a new Danish study finds.
Risk for Dementia Diagnosis Up for Seniors With Schizophrenia drugs
June 25, 2021
Older adults with schizophrenia have an increased risk for receiving a diagnosis of dementia compared with those without serious mental illness (SMI), according to a study published in the June issue of JAMA Psychiatry.
FDA approves Alkermes’ Lybalvi for schizophrenia treatment pharmaceutical-technology
June 02, 2021
The US Food and Drug Administration (FDA) has approved Alkermes’ Lybalvi as a treatment for adults with schizophrenia and for bipolar I disorder as maintenance monotherapy.
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II drugs
May 24, 2021
BioXcel today announced that FDA has accepted for filing NDA for BXCL501,orally dissolving thin film formulation of dexmedetomidine,for the acute treatment of agitation associated with schizophrenia and Bipolar disorders I and II
Luvadaxistat Study Results Did Not Meet Primary Endpoint americanpharmaceuticalreview
March 08, 2021
Neurocrine Biosciences announced investigational drug luvadaxistat did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseline on the PANSS NSFS at Day 84.
Novel shows promise in Phase II schizophrenia trial europeanpharmaceuticalreview
February 26, 2021
KarXT significantly reduced both positive and negative of symptoms of schizophrenia without the common problematic side effects of current antipsychotic therapies.
Ben-Gurion Researchers Develop Novel Method for Personalizing Clozapine Dose americanpharmaceuticalreview
February 19, 2021
Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel method for accurately monitoring blood levels of the antipsychotic drug, clozapine, using a blood drop from a finger prick.
Psychiatry Consortium funds project investigating new schizophrenia treatments pharmatimes
January 26, 2021
The international Psychiatry Consortium has funded its first project – a partnership which will investigate a new drug target for the treatment of schizophrenia.
New system could deliver schizophrenia medicine directly to brain europeanpharmaceuticalreview
January 20, 2021
A team has created a nasal spray as a drug delivery system to get schizophrenia medication directly to the brain.

Previous page 1 2 3 4 5 Next page